Saadatnia Mohammad, Salehi Mansour, Movahedian Ahmad, Shariat Seyed Ziaeddin Samsam, Salari Mehri, Tajmirriahi Marzieh, Asadimobarakeh Elham, Salehi Rasoul, Amini Gilda, Ebrahimi Homa, Kheradmand Ehsan
Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Genetic, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Med Sci. 2015 Jun;20(6):554-62. doi: 10.4103/1735-1995.165956.
Factor V G1691A (FV Leiden), FII GA20210, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are the most common genetic risk factors for thromboembolism in the Western countries. However, there is rare data in Iran about cerebral venous and sinus thrombosis (CVST) patients. The aim of this study was to evaluate the frequency of common genetic thrombophilic factors in CVST patients.
Forty consequently CVST patients from two University Hospital in Isfahan University of Medical Sciences aged more than 15 years from January 2009 to January 2011 were recruited. In parallel, 51 healthy subjects with the same age and race from similar population selected as controls. FV Leiden, FII GA20210, MTHFR C677T, and FV Cambridge gene mutations by polymerase chain reaction technique were evaluated in case and control groups.
FV Leiden, FII GA20210, and FV Cambridge gene mutations had very low prevalence in both case (5%, 2%, 0%) and control (2.5%, 0%, 0%) and were not found any significant difference between groups. MTHFR C677T mutations was in 22 (55%) of patients in case group and 18 (35.5%) of control group (P = 0.09).
This study showed that the prevalence of FV Leiden, FII GA20210, and FV Cambridge were low. Laboratory investigations of these mutations as a routine test for all patients with CVST may not be cost benefit.
因子V G1691A(FV莱顿突变)、凝血因子II GA20210和亚甲基四氢叶酸还原酶(MTHFR)C677T突变是西方国家血栓栓塞最常见的遗传风险因素。然而,伊朗关于脑静脉窦血栓形成(CVST)患者的数据很少。本研究的目的是评估CVST患者中常见遗传性血栓形成倾向因素的频率。
选取2009年1月至2011年1月期间,来自伊斯法罕医科大学两所大学医院的40例年龄超过15岁的CVST患者。同时,从相似人群中选取51名年龄和种族相同的健康受试者作为对照。通过聚合酶链反应技术对病例组和对照组进行FV莱顿突变、凝血因子II GA20210、MTHFR C677T和FV剑桥基因突变评估。
FV莱顿突变、凝血因子II GA20210和FV剑桥基因突变在病例组(5%、2%、0%)和对照组(2.5%、0%、0%)中的患病率都非常低,两组之间未发现任何显著差异。MTHFR C677T突变在病例组22例(55%)患者和对照组18例(35.5%)患者中存在(P = 0.09)。
本研究表明,FV莱顿突变、凝血因子II GA20210和FV剑桥基因突变的患病率较低。对所有CVST患者进行这些突变的实验室检查作为常规检查可能不具有成本效益。